A Phase I Trial Of G3139 (BCL-2 Antisense, NSC 683428, IND 58842) Combined With Cytotoxic Chemotherapy In Relapsed Childhood Solid Tumours.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Oblimersen (Primary) ; Cyclophosphamide; Dexrazoxane; Doxorubicin; Filgrastim
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 23 Nov 2006 Status change
- 24 Aug 2005 New trial record.